Vestre Viken Hospital Trust

Ultimovacs ASA halts LUNGVAC trial recruitment due to slow enrollment, driven by new NSCLC treatments. 31 enrolled patients will continue treatment, with topline data expected in H1 2025. Ultimovacs also conducts Phase II DOVACC trial for ovarian cancer and pre-clinical research on a novel drug conjugation platform, with updates planned by end of 2024.

Ultimovacs ASA halts recruitment for LUNGVAC trial due to slow enrollment, driven by new NSCLC treatments. All 31 enrolled patients will continue treatment, with topline data expected in H1 2025. Ultimovacs also advances UV1 in ovarian cancer and explores a novel drug conjugation platform.

Ultimovacs ASA halts recruitment for LUNGVAC trial due to slow enrollment, driven by new NSCLC treatment options. All 31 enrolled patients will be treated, with topline data expected in H1 2025. Ultimovacs continues to investigate UV1 in ovarian cancer and pre-clinical research on a novel drug conjugation platform.